Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on May 13, 2022. The report serves to announce the Company's financial results for the quarter ended March 31, 2022. The registrant is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the Exhibit 99.1 Press Release dated May 13, 2022, as they are not present in this 8-K text.
- Confirm the distinction between the company name in the metadata request (Opus Genetics) and the actual registrant (Ocuphire Pharma).
- Review the full press release for any forward-looking statements or clinical trial updates that may impact future guidance.
- Check the Company's cash runway and burn rate details in the referenced exhibit to assess liquidity risks.